Guy A. Young, MD

Title(s)Professor of Pediatrics (Clinical Scholar)
SchoolKeck School of Medicine of Usc
AddressCHL Mail Stop 54
Off Campus
Los Angeles CA 90089
Phone+1 323 361 4628
vCardDownload vCard

    Collapse Biography 
    Collapse Awards and Honors
    National Hemophilia Foundation2013Physician of the Year

    Collapse Overview 
    Collapse Overview
    Following medical school, I completed my residency in pediatrics at Schneider Children's Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children's National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children's Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children's Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

    Collapse Research 
    Collapse Research Activities and Funding
    Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH R01HL095110Sep 26, 2008 - Jan 31, 2013
    Role: Principal Investigator
    FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH R01FD003091Sep 20, 2006 - May 31, 2009
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Required Scholarly Project Mentor

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis (ATLAS-PPX). Blood. 2024 Mar 07. Kenet G, Nolan B, Zülfikar OB, Antmen B, Kampmann P, Matsushita T, You CW, Vilchevska K, Bagot CN, Sharif A, Peyvandi F, Young G, Negrier CG, Chi J, Kittner B, Sussebach C, Shammas F, Mei B, Andersson SR, Kavakli K. PMID: 38452197.
      View in: PubMed   Mentions:    Fields:    
    2. How I treat pediatric venous thromboembolism in the DOAC era. Blood. 2024 Feb 01; 143(5):389-403. Bhat RV, Young G, Sharathkumar AA. PMID: 37390311; PMCID: PMC10862368.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks. Res Pract Thromb Haemost. 2024 Jan; 8(1):102306. Kiialainen A, Adamkewicz JI, Petry C, Oldenburg J, Pipe SW, Young G, Mahlangu J, Lehle M, Niggli M, Castaman G, Jiménez-Yuste V, Shima M, Négrier C, Schmitt C. PMID: 38282901; PMCID: PMC10818085.
      View in: PubMed   Mentions:
    4. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b, open-label trial. Blood. 2023 Dec 21. Pipe SW, Collins PW, Dhalluin C, Kenet G, Schmitt C, Buri M, Jiménez-Yuste V, Peyvandi F, Young G, Oldenburg J, Mancuso ME, Kavakli K, Kiialainen A, Deb S, Niggli M, Chang T, Lehle M, Fijnvandraat K. PMID: 38127586.
      View in: PubMed   Mentions: 1     Fields:    Translation:CTClinical Trials
    5. Delivery of gene therapy in haemophilia treatment centres in the United States: Practical aspects of preparedness and implementation. Haemophilia. 2023 Nov; 29(6):1430-1441. Pipe S, Douglas K, Hwang N, Young G, Patel P, Fogarty P. PMID: 37747421.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Corrigendum to 'Evaluation of Venous Thromboembolism Risk Factors Reveals Subtype Heterogenicity in Children with Central Venous Catheters: A Multi-Center Study from the CHAT Consortium' [Journal of Thrombosis and Haemostasis 21/9 (2023) 2441 - 2450]. J Thromb Haemost. 2023 Dec; 21(12):3658. Jaffray J, Mosha M, Branchford B, Goldenberg NA, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Amankwah EK. PMID: 37741798.
      View in: PubMed   Mentions:    Fields:    
    7. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature. Res Pract Thromb Haemost. 2023 Aug; 7(6):102194. Kizilocak H, Guerrera MF, Young G. PMID: 37732158; PMCID: PMC10507376.
      View in: PubMed   Mentions:
    8. Prophylaxis with a recombinant factor VIII Fc in hemophilia A: long-term follow-up on joint health, efficacy, and safety from phase 3 studies in children and adults. Res Pract Thromb Haemost. 2023 Aug; 7(6):102180. Konkle BA, Oldenburg J, Pasi J, Kulkarni R, Nolan B, Mahlangu J, Young G, Brown SA, Pabinger I, Shapiro A, Négrier C, Blanchette V, Ragni MV, Dumont J, Lethagen S. PMID: 37753224; PMCID: PMC10518483.
      View in: PubMed   Mentions:
    9. Efficacy and safety evaluation of eptacog beta (coagulation factor VIIa [recombinant]-jncw) for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2023 Jul-Dec; 16(10):715-729. Pipe SW, Dunn AL, Young G. PMID: 37602448.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. The immunogenicity, safety, and efficacy of N8-GP in previously untreated patients with severe hemophilia A: pathfinder6 end-of-trial results. J Thromb Haemost. 2023 11; 21(11):3109-3116. Kenet G, Young G, Chuansumrit A, Matsushita T, Yadav V, Zak M, Male C. PMID: 37597724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Effects of PK-guided prophylaxis on clinical outcomes and FVIII consumption for patients with moderate to severe Haemophilia A. Haemophilia. 2023 Sep; 29(5):1234-1242. Young G, Callaghan MU, Balasa V, Soni A, Ahuja S, Roberts JC, Simpson ML, Kizilocak H, Frick A, Mokdad AG, Xing S, Caicedo J. PMID: 37553998.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    12. Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: Real-world retrospective multi-institutional cohort. Am J Hematol. 2023 10; 98(10):E285-E287. Batsuli G, Wheeler AP, Weyand AC, Sidonio RF, Young G. PMID: 37471655.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Time to revisit the classification of hemophilia: if it ain't broke, don't fix it! J Thromb Haemost. 2023 07; 21(7):1755-1756. Young G, Makris M. PMID: 37330266.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors. Int J Lab Hematol. 2023 Aug; 45(4):413-424. Meijer P, Peyvandi F, Young G, Pruthi R, de Lima Montalvão S, Kitchen S. PMID: 37287431.
      View in: PubMed   Mentions:    Fields:    
    15. Nonfactor Therapies for Hemophilia. Hemasphere. 2023 Jun; 7(6):e911. Young G. PMID: 37292115; PMCID: PMC10247213.
      View in: PubMed   Mentions:
    16. Antithrombin lowering in hemophilia: a closer look at fitusiran. Res Pract Thromb Haemost. 2023 May; 7(4):100179. Young G, Lenting PJ, Croteau SE, Nolan B, Srivastava A. PMID: 37358958; PMCID: PMC10285540.
      View in: PubMed   Mentions:
    17. Evaluation of venous thromboembolism risk factors reveals subtype heterogenicity in children with central venous catheters: a multicenter study from the Children's Hospital Acquired Thrombosis consortium. J Thromb Haemost. 2023 09; 21(9):2441-2450. Jaffray J, Mosha M, Branchford B, Goldenberg NA, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Amankwah EK. PMID: 37100395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial. Lancet. 2023 04 29; 401(10386):1427-1437. Young G, Srivastava A, Kavakli K, Ross C, Sathar J, You CW, Tran H, Sun J, Wu R, Poloskey S, Qiu Z, Kichou S, Andersson S, Mei B, Rangarajan S. PMID: 37003287.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    19. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023 03; 16(sup1):107-127. Ragni MV, Young G, Batsuli G, Bisson E, Carpenter SL, Croteau SE, Cuker A, Curtis RG, Denne M, Ewenstein B, Federizo A, Frick N, Funkhouser K, George LA, Hoots WK, Jobe SM, Krava E, Langmead CJ, Lewis RJ, López J, Malec L, Mann Z, Miles ME, Neely E, Neufeld EJ, Pierce GF, Pipe SW, Pitler LR, Raffini L, Schnur KM, Shavit JA. PMID: 36920855.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    20. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A. Blood Adv. 2023 02 28; 7(4):620-629. Male C, Königs C, Dey S, Matsushita T, Millner AH, Zak M, Young G, Kenet G. PMID: 35858373; PMCID: PMC9979760.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    21. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B. N Engl J Med. 2023 02 23; 388(8):706-718. Pipe SW, Leebeek FWG, Recht M, Key NS, Castaman G, Miesbach W, Lattimore S, Peerlinck K, Van der Valk P, Coppens M, Kampmann P, Meijer K, O'Connell N, Pasi KJ, Hart DP, Kazmi R, Astermark J, Hermans CRJR, Klamroth R, Lemons R, Visweshwar N, von Drygalski A, Young G, Crary SE, Escobar M, Gomez E, Kruse-Jarres R, Quon DV, Symington E, Wang M, Wheeler AP, Gut R, Liu YP, Dolmetsch RE, Cooper DL, Li Y, Goldstein B, Monahan PE. PMID: 36812434.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    22. The dosing conundrum of emicizumab: To waste product or not? Res Pract Thromb Haemost. 2023 Feb; 7(2):100087. Young G. PMID: 36908771; PMCID: PMC9999193.
      View in: PubMed   Mentions:
    23. Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12793. Abrams CM, Jaffray J, Stillings A, Branchford BR, Young G, Goldenberg NA, Abajas YL, CHAT Consortium Investigators, VTE Risk Factors and Thromboprophylaxis Working Group of the Pediatric and Neonatal Thrombosis and H, Fargo J, Crary S, Kumar R, Woods G, Narang S, Cooper J, Silvey M, Garland K, Mahajerin A, Luchtman-Jones L, Torres M, Wright J, Pahl K, Armstrong K, Braunreiter C, Bakeer N, Sochet A, Hogan M, Gupta S, Knoll C, Hege K, Schaefer B, Panigrahi A, Thornburg C, Shimano K, Ahuja S, Weyand A, Boucher A, Abajas Y, Subbaswamy A, Khan O, Druzgal C, Maida D, Wheeler A, Malec L, Branchford B, Kucine NE, Prozora S. PMID: 38024326; PMCID: PMC10656282.
      View in: PubMed   Mentions:
    24. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab. Haemophilia. 2022 Oct 26. Kizilocak H, Marquez-Casas E, Malvar J, Young G. PMID: 36287631.
      View in: PubMed   Mentions: 4     Fields:    
    25. Risk factors for hospital acquired venous thromboembolism in congenital heart disease patients: A report from the children's hospital acquired thrombosis (CHAT) consortium. Thromb Res. 2022 12; 220:116-120. Silvey M, Nguyen ATH, Amankwah EK, McElwaine E, Branchford B, Stillings A, Krava E, Young G, Goldenberg N, Jaffray J. PMID: 36334398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    26. Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital-Acquired Thrombosis consortium. Res Pract Thromb Haemost. 2022 Oct; 6(7):e12810. Stephens ET, Nguyen ATH, Jaffray J, Branchford B, Amankwah EK, Goldenberg NA, Faustino EVS, Zakai NA, Stillings A, Krava E, Young G, Fargo JH. PMID: 36254253; PMCID: PMC9561357.
      View in: PubMed   Mentions:
    27. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Adv. 2022 Aug 08. Kruse-Jarres R, Peyvandi F, Oldenburg J, Chang T, Chebon S, Doral MY, Croteau SE, Lambert T, Kempton CL, Pipe SW, Ko RH, Trzaskoma B, Dhalluin C, Bienz NS, Niggli M, Lehle M, Paz-Priel I, Young G, Jiménez-Yuste V. PMID: 35939785.
      View in: PubMed   Mentions: 8     Fields:    
    28. Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life. J Adv Pract Oncol. 2022 May; 13(Suppl 3):7-20. Escobar MA, Leissinger C, Young G. PMID: 35769336; PMCID: PMC9236157.
      View in: PubMed   Mentions:
    29. Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors. Blood Adv. 2022 06 14; 6(11):3422-3432. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Šalek S, Oldenburg J, Chowdary P. PMID: 35290453; PMCID: PMC9198939.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    30. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul; 28(4):548-556. Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA, Shapiro AD. PMID: 35475308; PMCID: PMC9542908.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    31. Direct oral anticoagulants for use in paediatrics. Lancet Child Adolesc Health. 2022 03; 6(3):207-214. Jaffray J, Young G. PMID: 35033222.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    32. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children's Hospital-Acquired Thrombosis Consortium. Pediatr Crit Care Med. 2022 01 01; 23(1):e1-e9. Jaffray J, Mahajerin A, Branchford B, Nguyen ATH, Faustino EVS, Silvey M, Croteau SE, Fargo JH, Cooper JD, Bakeer N, Zakai NA, Stillings A, Krava E, Amankwah EK, Young G, Goldenberg NA. PMID: 34406168; PMCID: PMC8738123.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    33. Can we do something about ICH in hemophilia? Blood. 2021 12 30; 138(26):2750-2751. Young G. PMID: 34967868.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    34. Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Blood Cancer. 2022 03; 69(3):e29522. Carmona R, Kizilocak H, Marquez-Casas E, Vasquez S, Ji L, Ko RH, Young G, Jaffray J. PMID: 34963026.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    35. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response. Thromb Haemost. 2022 Jun; 122(6):913-925. Chowdary P, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Cooper A, Scalfaro E, Tiede A. PMID: 34865209; PMCID: PMC9251711.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    36. Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children. J Pediatr. 2022 01; 240:14-23. Male C, Monagle P, Albisetti M, Brandão LR, Young G. PMID: 34687696.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium. J Thromb Haemost. 2022 01; 20(1):133-137. Jaffray J, Baumann Kreuziger L, Branchford B, Wee CP, Faustino EVS, Zakai NA, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Stillings A, Krava E, Young G, Goldenberg NA. PMID: 34623749.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    38. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931. Escobar M, Castaman G, Boix SB, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha IH, Négrier C, Quon D, Recht M, Schved JF, Shapiro AD, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska KV, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Macie C, Wilkinson TA, Kessler C. PMID: 34636112; PMCID: PMC9292935.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    39. Emerging drugs for hemophilia A: insights into phase II and III clinical trials. Expert Opin Emerg Drugs. 2021 12; 26(4):337-350. Kizilocak H, Young G. PMID: 34601977.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    40. Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2022 Jan; 28(1):27-35. Tiede A, Hampton K, Jiménez-Yuste V, Young G, Benchikh El Fegoun S, Chowdary P. PMID: 34562332.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    41. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021 Sep; 27(5):730-735. Kizilocak H, Marquez-Casas E, Malvar J, Carmona R, Young G. PMID: 34115433.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    42. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making. Haemophilia. 2021 Sep; 27(5):724-729. Mason JA, Young G. PMID: 34085367.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Management of children with hemophilia A: How emicizumab has changed the landscape. J Thromb Haemost. 2021 07; 19(7):1629-1637. Young G. PMID: 33872458.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    44. Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242. Callaghan MU, Negrier C, Paz-Priel I, Chang T, Chebon S, Lehle M, Mahlangu J, Young G, Kruse-Jarres R, Mancuso ME, Niggli M, Howard M, Bienz NS, Shima M, Jiménez-Yuste V, Schmitt C, Asikanius E, Levy GG, Pipe SW, Oldenburg J. PMID: 33512413; PMCID: PMC8065240.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    45. Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opin Drug Saf. 2021 Apr; 20(4):387-396. Wang CP, Young G, Thornburg CD. PMID: 33612049.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    46. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021 02 11; 137(6):763-774. Konkle BA, Walsh CE, Escobar MA, Josephson NC, Young G, von Drygalski A, McPhee SWJ, Samulski RJ, Bilic I, de la Rosa M, Reipert BM, Rottensteiner H, Scheiflinger F, Chapin JC, Ewenstein B, Monahan PE. PMID: 33067633; PMCID: PMC7885820.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCellsCTClinical Trials
    47. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27(2):211-220. Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. PMID: 33550614.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    48. Key questions in the new hemophilia era: update on concomitant use of FVIII and emicizumab in hemophilia A patients with inhibitors. Expert Rev Hematol. 2021 02; 14(2):143-148. Carcao M, Mancuso ME, Young G, Jiménez-Yuste V. PMID: 33499681.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    49. Comparison of bypassing agents in patients on emicizumab using global hemostasis assays. Haemophilia. 2021 Jan; 27(1):164-172. Kizilocak H, Marquez-Casas E, Phei Wee C, Malvar J, Carmona R, Young G. PMID: 33245833.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    50. Emicizumab-Induced Seronegative Full-House Lupus Nephritis in a Child. Pediatrics. 2020 11; 146(5). Chehade H, Cachat F, Beck-Popovic M, Rotman S, Diezi L, Albisetti M, Alberio L, Young G, Rizzi M. PMID: 33122347.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    51. Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018. Mancuso ME, Mahlangu J, Sidonio R, Trask P, Uguen M, Chang T, Shima M, Young G, Oldenburg J, von Mackensen S. PMID: 33084175; PMCID: PMC7821108.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Thromb Haemost. 2021 Mar; 121(3):351-360. Schmitt C, Adamkewicz JI, Xu J, Petry C, Catalani O, Young G, Negrier C, Callaghan MU, Levy GG. PMID: 33086400; PMCID: PMC7895541.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    53. Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). Blood Adv. 2020 10 13; 4(19):4632-4639. Thom K, Lensing AWA, Nurmeev I, Bajolle F, Bonnet D, Kenet G, Massicotte MP, Karakas Z, Palumbo JS, Saracco P, Amedro P, Chain J, Chan AK, Ikeyama T, Lam JCM, Gauger C, Pap ÁF, Majumder M, Kubitza D, Smith WT, Berkowitz SD, Prins MH, Monagle P, Young G, Male C. PMID: 33002131; PMCID: PMC7556137.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    54. Implications of the first FDA-approved anticoagulant in pediatrics: One ship has sailed but the next ones are at the dock. Pediatr Blood Cancer. 2020 12; 67(12):e28731. Young G. PMID: 32969168.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium. J Pediatr. 2021 01; 228:252-259.e1. Jaffray J, Branchford B, Goldenberg N, Malvar J, Croteau SE, Silvey M, Fargo JH, Cooper JD, Bakeer N, Sposto R, Ji L, Zakai NA, Faustino EVS, Stillings A, Krava E, Young G, Mahajerin A. PMID: 32920105; PMCID: PMC7752847.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    56. Nonacog beta pegol (N9-GP) in hemophilia B: First report on safety and efficacy in previously untreated and minimally treated patients. Res Pract Thromb Haemost. 2020 Oct; 4(7):1101-1113. Chan AK, Alamelu J, Barnes C, Chuansumrit A, Garly ML, Meldgaard RM, Young G. PMID: 33134776; PMCID: PMC7590314.
      View in: PubMed   Mentions: 9  
    57. Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation. J Thromb Haemost. 2020 09; 18(9):2205-2208. Harkins Druzgal C, Kizilocak H, Brown J, Sennett M, Young G. PMID: 32544268.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    58. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemost. 2020 07; 18(7):1672-1685. Young G, Lensing AWA, Monagle P, Male C, Thelen K, Willmann S, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bajolle F, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Beyer-Westendorf J, Martinelli I, Massicotte MP, Smith WT, Berkowitz SD, Schmidt S, Price V, Prins MH, Kubitza D, EINSTEIN-Jr. Phase 3 Investigators. PMID: 32246743.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    59. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Res Pract Thromb Haemost. 2020 Jul; 4(5):886-892. van Ommen CH, Albisetti M, Chan AK, Estepp J, Jaffray J, Kenet G, Young G, Dave J, Grosso MA, Duggal A. PMID: 32685899; PMCID: PMC7354398.
      View in: PubMed   Mentions: 7  
    60. FondaKIDS III: A long-term retrospective cohort study of fondaparinux for treatment of venous thromboembolism in children. Pediatr Blood Cancer. 2020 08; 67(8):e28295. Shen X, Wile R, Young G. PMID: 32307822.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    61. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study. Haemophilia. 2020 May; 26(3):494-502. Nolan B, Mahlangu J, Pabinger I, Young G, Konkle BA, Barnes C, Nogami K, Santagostino E, Pasi KJ, Khoo L, Winding B, Yuan H, Fruebis J, Rudin D, Oldenburg J. PMID: 32227570; PMCID: PMC7384031.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    62. Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms. Expert Rev Hematol. 2020 04; 13(4):313-321. Lillicrap D, Fijnvandraat K, Young G, Mancuso ME. PMID: 32186928.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    63. Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood. 2020 01 16; 135(3):220-226. Jaffray J, Witmer C, O'Brien SH, Diaz R, Ji L, Krava E, Young G. PMID: 31909784.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    64. Comparative validation study of risk assessment models for pediatric hospital-acquired venous thromboembolism. J Thromb Haemost. 2020 03; 18(3):633-641. Mahajerin A, Jaffray J, Branchford B, Stillings A, Krava E, Young G, Goldenberg NA, Faustino EVS. PMID: 31808292.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    65. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138. Young G, Liesner R, Chang T, Sidonio R, Oldenburg J, Jiménez-Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Uguen M, Doral MY, Wright LY, Schmitt C, Levy GG, Shima M, Mancuso ME. PMID: 31697801; PMCID: PMC6908828.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCTClinical Trials
    66. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019 11 28; 134(22):1973-1982. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, Chowdary P, Eichler H, Jiménez-Yuste V, Kavakli K, Matsushita T, Poulsen LH, Wheeler AP, Young G, Zupancic-Salek S, Oldenburg J. PMID: 31444162; PMCID: PMC6895373.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    67. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020 Jan; 7(1):e18-e27. Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P, EINSTEIN-Jr Phase 3 Investigators. PMID: 31699660.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    68. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019 Oct; 6(10):e500-e509. Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D, EINSTEIN-Jr Phase 2 Investigators. PMID: 31420317.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    69. Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data. J Blood Med. 2019; 10:243-250. Escobar MA, Walsh CE, Cooper DL, Young G. PMID: 31413650; PMCID: PMC6662862.
      View in: PubMed   Mentions:
    70. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol. 2019; 10:2040620719860025. Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. PMID: 31275538; PMCID: PMC6598318.
      View in: PubMed   Mentions: 12  
    71. Diagnosis and treatment of hemophilia. Clin Adv Hematol Oncol. 2019 Jun; 17(6):344-351. Kizilocak H, Young G. PMID: 31437138.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    72. How I treat children with haemophilia and inhibitors. Br J Haematol. 2019 08; 186(3):400-408. Young G. PMID: 31069799.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    73. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia. 2019 Jul; 25(4):676-684. Carcao M, Escuriola-Ettingshausen C, Santagostino E, Oldenburg J, Liesner R, Nolan B, Bátorová A, Haya S, Young G, Future of Immunotolerance Treatment Group. PMID: 31033112; PMCID: PMC6850066.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    74. Why plasma-derived factor VIII? Haemophilia. 2019 May; 25(3):e183-e185. Aledort L, Carpenter SL, Cuker A, Kulkarni R, Recht M, Young G, Leissinger C. PMID: 30866124.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    75. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice. J Thromb Haemost. 2019 Apr; 17(4):567-573. Young GA, Perry DJ, International Prophylaxis Study Group (IPSG). PMID: 30667575.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    76. Inhibitors: A Need for Eradication? Acta Haematol. 2019; 141(3):151-155. Santagostino E, Young G, Escuriola Ettingshausen C, Jimenez-Yuste V, Carcao M. PMID: 30783066.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    77. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thromb J. 2018; 16:34. Lensing AWA, Male C, Young G, Kubitza D, Kenet G, Patricia Massicotte M, Chan A, Molinari AC, Nowak-Goettl U, Pap ÁF, Adalbo I, Smith WT, Mason A, Thelen K, Berkowitz SD, Crowther M, Schmidt S, Price V, Prins MH, Monagle P. PMID: 30598642; PMCID: PMC6302520.
      View in: PubMed   Mentions: 14  
    78. Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia. Am J Hematol. 2019 02; 94(2):249-256. Ramiz S, Hartmann J, Young G, Escobar MA, Chitlur M. PMID: 30328141.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    79. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018; 16:31. Kubitza D, Willmann S, Becka M, Thelen K, Young G, Brandão LR, Monagle P, Male C, Chan A, Kennet G, Martinelli I, Saracco P, Lensing AWA. PMID: 30534007; PMCID: PMC6278122.
      View in: PubMed   Mentions: 13  
    80. The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44. Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S. PMID: 30427582.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    81. Implementing emicizumab in hemophilia inhibitor management: emicizumab should be prescribed after tolerance. Blood Adv. 2018 10 23; 2(20):2780-2782. Young G. PMID: 30352951; PMCID: PMC6199657.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    82. Emicizumab for hemophilia A with factor VIII inhibitors. Expert Rev Hematol. 2018 11; 11(11):835-846. Young G, Callaghan M, Dunn A, Kruse-Jarres R, Pipe S. PMID: 30278802.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    83. The importance of inhibitor eradication in clinically complicated hemophilia A patients. Expert Rev Hematol. 2018 11; 11(11):857-862. Oldenburg J, Young G, Santagostino E, Escuriola Ettingshausen C. PMID: 30286680.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. Once-weekly prophylaxis with 40 IU/kg nonacog beta pegol (N9-GP) achieves trough levels of >15% in patients with haemophilia B: Pooled data from the paradigm™ trials. Haemophilia. 2018 Nov; 24(6):911-920. Oldenburg J, Carcao M, Lentz SR, Mahlangu J, Mancuso ME, Matsushita T, Négrier C, Clausen WHO, Ehrenforth S, Young G. PMID: 30248217.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    85. Obesity and risk for venous thromboembolism from contemporary therapy for pediatric acute lymphoblastic leukemia. Thromb Res. 2018 05; 165:44-50. Prasca S, Carmona R, Ji L, Ko RH, Bhojwani D, Rawlins YA, Mittelman SD, Young G, Orgel E. PMID: 29567586; PMCID: PMC7522001.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    86. A contemporary look at FVIII inhibitor development: still a great influence on the evolution of hemophilia therapies. Expert Rev Hematol. 2018 02; 11(2):87-97. Santagostino E, Young G, Carcao M, Mannucci PM, Halimeh S, Austin S. PMID: 29258406.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    87. Novel therapies and current clinical progress in hemophilia A. Ther Adv Hematol. 2018 Feb; 9(2):49-61. Balkaransingh P, Young G. PMID: 29387330; PMCID: PMC5768270.
      View in: PubMed   Mentions: 23  
    88. A multi-institutional registry of pediatric hospital-acquired thrombosis cases: The Children's Hospital-Acquired Thrombosis (CHAT) project. Thromb Res. 2018 01; 161:67-72. Jaffray J, Mahajerin A, Young G, Goldenberg N, Ji L, Sposto R, Stillings A, Krava E, Branchford B. PMID: 29207321.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    89. Deep vein thrombosis in pediatric patients. Pediatr Blood Cancer. 2018 03; 65(3). Jaffray J, Young G. PMID: 29115714.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    90. Anticoagulation Therapies in Children. Pediatr Clin North Am. 2017 12; 64(6):1257-1269. Young G. PMID: 29173784.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    91. How I treat pediatric venous thromboembolism. Blood. 2017 09 21; 130(12):1402-1408. Young G. PMID: 28774877; PMCID: PMC5813720.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    92. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries. Am J Hematol. 2017 Sep; 92(9):940-945. Young G, Escobar MA, Pipe SW, Cooper DL. PMID: 28589615.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    93. Pediatric Anticoagulation: Time for a New Paradigm? J Pediatr. 2017 10; 189:21-23. Takahashi M, Young G. PMID: 28705651.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    94. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 08 31; 377(9):809-818. Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Valente N, Asikanius E, Levy GG, Windyga J, Shima M. PMID: 28691557.
      View in: PubMed   Mentions: 292     Fields:    Translation:HumansCTClinical Trials
    95. Anticoagulation in children: Making the most of little patients and little evidence. Blood Cells Mol Dis. 2017 09; 67:48-53. Young G, Male C, van Ommen CH. PMID: 28552476.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017 06 02; 117(6):1023-1030. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M, Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). PMID: 28357444.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    97. Treatment of Venous Thromboembolism in Pediatric Patients. Front Pediatr. 2017; 5:26. Malec L, Young G. PMID: 28293549; PMCID: PMC5328974.
      View in: PubMed   Mentions: 11  
    98. The perils of rivaroxaban in younger patients. Thromb Res. 2016 12; 148:154-155. Young G. PMID: 28340957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    99. Thromboelastographic characterization of the activated clotting system in children with sickle cell trait or sickle cell disease. Thromb Res. 2017 Mar; 151:44-50. Gupta S, Carmona R, Malvar J, Young G. PMID: 28110132.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    100. Impact of high-risk thrombophilia status on recurrence among children with a first non-central-venous-catheter-associated VTE: an observational multicentre cohort study. Br J Haematol. 2016 Oct; 175(1):133-40. Limperger V, Kenet G, Goldenberg NA, Heller C, Holzhauer S, Junker R, Klostermeier UC, Knoefler R, Kurnik K, Krümpel A, Mesters R, Stach M, Young G, Nowak-Göttl U. PMID: 27329967.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    101. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016 May 26; 374(21):2054-64. Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR. PMID: 27223147.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    102. Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A. Thromb Haemost. 2016 07 04; 116(1):1-8. Mahlangu JN, Ragni M, Gupta N, Rangarajan S, Klamroth R, Oldenburg J, Nogami K, Young G, Cristiano LM, Dong Y, Allen G, Pierce GF, Robinson B. PMID: 26962852.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    103. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016 May; 141:69-76. Young G, Collins PW, Colberg T, Chuansumrit A, Hanabusa H, Lentz SR, Mahlangu J, Mauser-Bunschoten EP, Négrier C, Oldenburg J, Patiroglu T, Santagostino E, Tehranchi R, Zak M, Karim FA. PMID: 26970716.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    104. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet. 2016 Jul 09; 388(10040):187-97. Peyvandi F, Garagiola I, Young G. PMID: 26897598.
      View in: PubMed   Mentions: 141     Fields:    Translation:Humans
    105. The bleeding newborn: A review of presentation, diagnosis, and management. Semin Fetal Neonatal Med. 2016 Feb; 21(1):44-9. Jaffray J, Young G, Ko RH. PMID: 26778526.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    106. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015; 9:1623-30. Chaugule SS, Hay JW, Young G. PMID: 26635471; PMCID: PMC4646600.
      View in: PubMed   Mentions: 12  
    107. Global assays in hemophilia. Semin Hematol. 2016 Jan; 53(1):40-5. Chitlur M, Young G. PMID: 26805906.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    108. Anticoagulants in children and adolescents. Hematology Am Soc Hematol Educ Program. 2015; 2015:111-6. Young G. PMID: 26637709.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    109. Evaluation of algorithms for the treatment of problem bleeding episodes in patients with hemophilia having inhibitors. Clin Appl Thromb Hemost. 2015 Jan; 21(1):10-8. Young G, Teitel J, d'Oiron R, Leissinger C, Berntorp E. PMID: 25343956.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    110. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6. Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C, paradigm 2 Investigators. PMID: 25261199; PMCID: PMC4271178.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    111. FondaKIDS II: long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events. Thromb Res. 2014 Sep; 134(3):643-7. Ko RH, Michieli C, Lira JL, Young G. PMID: 25087891.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    112. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. Clin Pharmacokinet. 2013 Nov; 52(11):967-80. Yee DL, O'Brien SH, Young G. PMID: 23797535.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    113. Developmental hemostasis: clinical implications from the fetus to the adolescent. Pediatr Clin North Am. 2013 Dec; 60(6):1407-17. Jaffray J, Young G. PMID: 24237979.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    114. Antithrombin III administration in neonates with congenital diaphragmatic hernia during the first three days of extracorporeal membrane oxygenation. J Pediatr Surg. 2013 Sep; 48(9):1837-42. Perry R, Stein J, Young G, Ramanathan R, Seri I, Klee L, Friedlich P. PMID: 24074654.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    115. Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs). Thromb Res. 2013 Nov; 132(5):527-30. Kanin M, Young G. PMID: 24055175.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    116. A novel approach for detecting hypercoagulability utilizing thromboelastography. Thromb Res. 2013 Apr; 131(4):352-6. Ko RH, Ji L, Young G. PMID: 23419411.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    117. Factor VIII inhibitors in hemophilia A: rationale and latest evidence. Ther Adv Hematol. 2013 Feb; 4(1):59-72. Witmer C, Young G. PMID: 23610614; PMCID: PMC3629762.
      View in: PubMed   Mentions: 68  
    118. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives. Blood. 2013 Mar 14; 121(11):1944-50. Young G, Sørensen B, Dargaud Y, Negrier C, Brummel-Ziedins K, Key NS. PMID: 23319573; PMCID: PMC3645054.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    119. Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). J Blood Med. 2012; 3:131-8. Young G, Solem CT, Hoffman K, Kabawat J, Pickard AS, Gut RZ, Cooper DL. PMID: 23152717; PMCID: PMC3496408.
      View in: PubMed   Mentions: 4  
    120. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors. Thromb Res. 2012 Dec; 130(6):864-70. Young G, Auerswald G, Jimenez-Yuste V, Lambert T, Morfini M, Santagostino E, Blanchette V. PMID: 22964026.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    121. Difficult clinical challenges in haemophilia: international experiential perspectives. Haemophilia. 2012 Jul; 18 Suppl 5:39-45. Forsyth AL, Giangrande P, Hay CR, Kenet G, Kessler CM, Knöbl PN, Llinás A, Santagostino E, Young G. PMID: 22757683.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    122. From boy to man: recommendations for the transition process in haemophilia. Haemophilia. 2012 Jul; 18 Suppl 5:27-32. Young G. PMID: 22757681.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    123. Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in children. Expert Rev Clin Pharmacol. 2012 Jul; 5(4):389-96. Ko RH, Young G. PMID: 22943118.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    124. Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A. Am J Hematol. 2012 Sep; 87(9):933-6. Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C, Young G, Soucie JM. PMID: 22733686; PMCID: PMC3645919.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    125. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia. 2012 Nov; 18(6):990-6. Young G, Cooper DL, Gut RZ, HTRS Investigators. PMID: 22631073.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    126. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program. 2012; 2012:362-8. Young G. PMID: 23233605.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    127. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. Semin Thromb Hemost. 2011 Oct; 37(7):802-9. Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. PMID: 22187403.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    128. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE). Haemophilia. 2012 May; 18(3):392-9. Young G, Shapiro AD, Walsh CE, Gruppo RA, Gut RZ, Cooper DL. PMID: 22171621.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    129. Old and new antithrombotic drugs in neonates and infants. Semin Fetal Neonatal Med. 2011 Dec; 16(6):349-54. Young G. PMID: 21816695.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors. Am Health Drug Benefits. 2011 Jul; 4(4):219-31. Bonnet P, Gringeri A, Gomperts E, Leissinger CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. PMID: 25126352; PMCID: PMC4125756.
      View in: PubMed   Mentions: 2  
    131. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia. 2011 Sep; 17(5):e849-57. Young G, Auerswald G, Jimenez-Yuste V, Konkle BA, Lambert T, Morfini M, Santagostino E, Blanchette V. PMID: 21418444.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    132. FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of age. Pediatr Blood Cancer. 2011 Dec 01; 57(6):1049-54. Young G, Yee DL, O'Brien SH, Khanna R, Barbour A, Nugent DJ. PMID: 21319285.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    133. Pediatric catheterization laboratory anticoagulation with bivalirudin. Catheter Cardiovasc Interv. 2011 Apr 01; 77(5):671-9. Forbes TJ, Hijazi ZM, Young G, Ringewald JM, Aquino PM, Vincent RN, Qureshi AM, Rome JJ, Rhodes JF, Jones TK, Moskowitz WB, Holzer RJ, Zamora R. PMID: 21433272.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    134. New anticoagulants in children: a review of recent studies and a look to the future. Thromb Res. 2011 Feb; 127(2):70-4. Young G. PMID: 21129768.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    135. Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1103-9. Young G, Boshkov LK, Sullivan JE, Raffini LJ, Cox DS, Boyle DA, Kallender H, Tarka EA, Soffer J, Hursting MJ. PMID: 21488155.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    136. Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing population. Blood Coagul Fibrinolysis. 2010 Sep; 21 Suppl 1:S7-10. Young G. PMID: 20855989.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    137. Pharmacokinetic and pharmacodynamic basis for effective argatroban dosing in pediatrics. J Clin Pharmacol. 2011 Jan; 51(1):19-28. Madabushi R, Cox DS, Hossain M, Boyle DA, Patel BR, Young G, Choi YM, Gobburu JV. PMID: 20421511.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    138. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. Circulation. 2010 Apr 27; 121(16):1838-47. Kenet G, Lütkhoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Günther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostásy K, Simioni P, Sträter RD, Young G, Nowak-Göttl U. PMID: 20385928.
      View in: PubMed   Mentions: 94     Fields:    Translation:Humans
    139. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia. 2010 May; 16(3):518-24. Young G, Zhang R, Miller R, Yassin D, Nugent DJ. PMID: 20028419.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    140. Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 children. Pediatr Blood Cancer. 2009 Aug; 53(2):179-83. Young G, Wicklund B, Neff P, Johnson C, Nugent DJ. PMID: 19415741.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    141. Bivalirudin for anticoagulation in children. Pediatr Blood Cancer. 2008 Dec; 51(6):798-801. Rayapudi S, Torres A, Deshpande GG, Ross MP, Wohrley JD, Young G, Tarantino MD. PMID: 18819124.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    142. Impact of inherited thrombophilia on venous thromboembolism in children: a systematic review and meta-analysis of observational studies. Circulation. 2008 Sep 23; 118(13):1373-82. Young G, Albisetti M, Bonduel M, Brandao L, Chan A, Friedrichs F, Goldenberg NA, Grabowski E, Heller C, Journeycake J, Kenet G, Krümpel A, Kurnik K, Lubetsky A, Male C, Manco-Johnson M, Mathew P, Monagle P, van Ommen H, Simioni P, Svirin P, Tormene D, Nowak-Göttl U. PMID: 18779442.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    143. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis. 2008 Jun; 19(4):276-82. Young G, Ebbesen LS, Viuff D, Di Paola J, Konkle BA, Negrier C, Pasi J, Ingerslev J. PMID: 18469548.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    144. New anticoagulants in children. Hematology Am Soc Hematol Educ Program. 2008; 245-50. Young G. PMID: 19074090.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    145. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia. 2008 Mar; 14(2):287-94. Young G, Shafer FE, Rojas P, Seremetis S. PMID: 18081834.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    146. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography. Blood Coagul Fibrinolysis. 2007 Sep; 18(6):547-53. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. PMID: 17762530.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    147. Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosis. J Thromb Haemost. 2007 Aug; 5(8):1654-9. Young G, Tarantino MD, Wohrley J, Weber LC, Belvedere M, Nugent DJ. PMID: 17663736.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    148. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis. 2007 Mar; 18(2):97-103. Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ. PMID: 17287624.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    149. Heparin use in children. Pediatr Res. 2007 Feb; 61(2):139-40. Young G. PMID: 17237710.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    150. Diagnosis and treatment of thrombosis in children: general principles. Pediatr Blood Cancer. 2006 May 01; 46(5):540-6. Young G. PMID: 16206194.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    151. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr. 2006 Apr; 148(4):489-94. Tarantino MD, Young G, Bertolone SJ, Kalinyak KA, Shafer FE, Kulkarni R, Weber LC, Davis ML, Lynn H, Nugent DJ, Acute ITP Study Group. PMID: 16647411.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    152. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood. 2006 Jul 01; 108(1):57-62. Lovejoy AE, Reynolds TC, Visich JE, Butine MD, Young G, Belvedere MA, Blain RC, Pederson SM, Ishak LM, Nugent DJ. PMID: 16556896.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    153. New approaches in the management of inhibitor patients. Acta Haematol. 2006; 115(3-4):172-9. Young G. PMID: 16549892.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    154. Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol. 2005 Dec; 27(12):666-9. Baserga M, Rosin M, Schoen M, Young G. PMID: 16344673.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    155. Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutations. J Pediatr Hematol Oncol. 2005 Nov; 27(11):590-3. Rook JL, Nugent DJ, Young G. PMID: 16282888.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    156. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005 Feb; 7(2):143-6. Grewal SS, Wynn R, Abdenur JE, Burton BK, Gharib M, Haase C, Hayashi RJ, Shenoy S, Sillence D, Tiller GE, Dudek ME, van Royen-Kerkhof A, Wraith JE, Woodard P, Young GA, Wulffraat N, Whitley CB, Peters C. PMID: 15714083.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    157. Therapy for haemophilia: recent advances and goals for the future. Expert Opin Emerg Drugs. 2005 Feb; 10(1):173-84. Young G, Aledort L. PMID: 15757411.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    158. Can we rise to yet another challenge? Prof Nurse. 2004 Sep; 20(1):6-7. Young G. PMID: 15468769.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    159. Current and future antithrombotic agents in children. Expert Rev Cardiovasc Ther. 2004 Jul; 2(4):523-34. Young G. PMID: 15225112.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    160. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion. 2004; 19(5):283-8. Young G, Yonekawa KE, Nakagawa P, Nugent DJ. PMID: 15506032.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    See more options in the Advanced Search tab

    Guy's Networks
    Concepts (292)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (17)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    NIH Funding Acknowledgment: Important - All publications resulting from the utilization of SC CTSI resources are required to credit the SC CTSI grant by including the NIH funding acknowledgment and must comply with the NIH Public Access Policy.

    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.